Skip to main contentSkip to navigation
Sirius Investors

Astria Therapeutics, Inc. (ATXS) Investment Research Dashboard

About Astria Therapeutics, Inc. (ATXS) stock analysis

Get live ATXS stock price $12.58, comprehensive Astria Therapeutics, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time ATXS stock data and investment insights.

12.58
0.00%Today
Market Cap
718.13M
Volume
3.06M
52W High
13.29
52W Low
3.56

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological di...

Company Information

CEO
Jill C. Milne
Sector
Healthcare
Industry
Biotechnology
Employees
78

Contact Information

Address
100 High Street
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: 0.02) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Astria Therapeutics, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Astria Therapeutics, Inc.
  • Investors should consider how Astria Therapeutics, Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

718.13M

P/E Ratio (TTM)

-5.88

Beta

0.02

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

81/100 ⭐⭐⭐⭐⭐

Overall
+0.3%
NYSE
-0.1%
NASDAQ
+0.8%
Sector1D1W1MP/EScore
Financial Services+0.1%+1.3%+2.0%19.3
82/100⭐⭐⭐⭐⭐
Healthcare+0.3%+2.8%+1.6%23.6
81/100⭐⭐⭐⭐⭐
Communication Services+0.8%-2.0%+2.3%22.2
70/100⭐⭐⭐⭐⭐
Consumer Defensive+1.1%+1.3%+0.1%29.0
66/100⭐⭐⭐⭐
Energy+0.9%+0.7%-1.3%19.7
64/100⭐⭐⭐⭐
Real Estate-0.4%+2.3%-1.5%29.6
54/100⭐⭐⭐
Basic Materials-0.4%+0.7%-1.5%25.0
46/100⭐⭐⭐
Utilities-1.0%+2.2%-2.2%25.6
44/100⭐⭐⭐
Consumer Cyclical+0.5%-1.4%-3.8%42.9
18/100
Industrials-0.8%-0.4%-9.2%30.6
13/100
Technology-1.9%-1.1%-5.6%42.0
12/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-27.